Add to ORKGA major challenge facing Congress is what changes, if any, to make to Medicare Part D. With the apparent failure of the Democrats\u27 attempt to remove the prohibition on government intervention in drug price negotiations, the party\u27s next steps are unclear. One suggested option is a plan administered by the Centers for Medicare and Medicaid Services (CMS), to compete with private plans and facilitate a transition to a more rational structure. We discuss issues surrounding the design of such a mechanism and how it might provide a transition toward a more rational and sustainable drug benefit in the longer term
Summary: Value-based insurance design (VBID) has emerged as a potentially viable approach to promote...
The Medicare Modernization Act of 2003 added a new outpatient pre-scription drug bene\u85t to Medica...
In 1965, Congress modeled Medicare’s original package of benefits after those offered by Blue Cross ...
Efforts to enact a prescription drug benefit in Medicare date back more than forty years. Since then...
Congress may reform drug pricing policies under Medicare Part D as part of a larger health reform ef...
After many years of debate, Congress recently approved a new, voluntary “Medicare Part D” benefit th...
Since January 2006 Medicare beneficiaries have the option to purchase prescription drug benefits fro...
The new Medicare prescription drug benefit, Medicare Plan D, signed into law by President Bush in 20...
The United States is a relatively free-pricing market for pharmaceutical manufacturers to set list p...
Under the 2022 Inflation Reduction Act, the Centers for Medicare and Medicaid Services (CMS) are abl...
Testimony issued by the General Accounting Office with an abstract that begins "The House Committee ...
The Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (MPDIMA) represents the...
and the ensuing rollout of the outpatient drug benefit in January 2006 have focused attention on ens...
The Medicare Prescription Drug, Improvement, and Modernization Act (MMA) of 2003 expands the role of...
When Congress was debating the Medicare drug benefit in 2003, there were many who advocated that Med...
Summary: Value-based insurance design (VBID) has emerged as a potentially viable approach to promote...
The Medicare Modernization Act of 2003 added a new outpatient pre-scription drug bene\u85t to Medica...
In 1965, Congress modeled Medicare’s original package of benefits after those offered by Blue Cross ...
Efforts to enact a prescription drug benefit in Medicare date back more than forty years. Since then...
Congress may reform drug pricing policies under Medicare Part D as part of a larger health reform ef...
After many years of debate, Congress recently approved a new, voluntary “Medicare Part D” benefit th...
Since January 2006 Medicare beneficiaries have the option to purchase prescription drug benefits fro...
The new Medicare prescription drug benefit, Medicare Plan D, signed into law by President Bush in 20...
The United States is a relatively free-pricing market for pharmaceutical manufacturers to set list p...
Under the 2022 Inflation Reduction Act, the Centers for Medicare and Medicaid Services (CMS) are abl...
Testimony issued by the General Accounting Office with an abstract that begins "The House Committee ...
The Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (MPDIMA) represents the...
and the ensuing rollout of the outpatient drug benefit in January 2006 have focused attention on ens...
The Medicare Prescription Drug, Improvement, and Modernization Act (MMA) of 2003 expands the role of...
When Congress was debating the Medicare drug benefit in 2003, there were many who advocated that Med...
Summary: Value-based insurance design (VBID) has emerged as a potentially viable approach to promote...
The Medicare Modernization Act of 2003 added a new outpatient pre-scription drug bene\u85t to Medica...
In 1965, Congress modeled Medicare’s original package of benefits after those offered by Blue Cross ...